Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation
We recommend
Current Reimbursement Conditions for the Dual Inhibitor IL-4/IL-13 Dupilumab
The biologic dupilumab is approved for the treatment of several diseases with type 2 inflammation. What is the current reimbursement situation in key indications? We summarize in the following brief overview.
Doc. Miloslav Salavec: We Still Encounter Delayed Initiation of Biological Treatment in AD and Many Other Diagnoses
Not all patients with atopic dermatitis (AD) who are indicated for biological treatment with…
Laboratory Safety of Dupilumab Treatment in Children with Atopic Dermatitis Aged 6 Months to 6 Years
Previous clinical studies in children aged 6–12 years with moderate-to-severe atopic dermatitis…
Articles on this topic
Is Dupilumab Effective in AD Therapy for Patients for Whom Cyclosporine A Fails or Cannot Be Given?
Severe forms of atopic dermatitis (AD) may require systemic therapy. However, the…
Dupilumab Now Covered for Atopic Dermatitis in Children Older Than 6 Years
Dupilumab is now fully covered by public health insurance for pediatric patients from 6 years…
Efficacy and Safety of Dupilumab in the Treatment of Atopic Dermatitis in Adolescents
In the pediatric population, atopic dermatitis (AD) has a relatively high prevalence, but…
Quick Relief from Severe AD Symptoms – Dupilumab for Children Aged 6 Years and Older
Children aged 6-12 with severe atopic dermatitis (AD) have very limited treatment options. The…
Alleviation of Asthma and Chronic Sinusitis Symptoms in Patients with Atopic Dermatitis Thanks to Dupilumab
An analysis of results in adult patients with moderate to severe atopic dermatitis, who also…
Therapy with Cyclosporine in the Context of the Coronavirus Pandemic
The rapid spread of the SARS-CoV-2 virus and the associated COVID-19 disease pandemic raises…
The safety of dupilumab allows treatment of atopic dermatitis without routine laboratory monitoring
The first comprehensive analysis of laboratory data from 3 clinical trials with dupilumab…
Is It Necessary to Discontinue Dupilumab in Patients with Atopic Dermatitis During the COVID-19 Pandemic?
Italian authors described their experiences with remote treatment of 200 atopic dermatitis…
ADCT – a simple tool for self-diagnosis of patients with severe atopic dermatitis
Atopic dermatitis (AD) is a chronic inflammatory disease not only of childhood. It can…
Dupilumab in the Treatment of Adolescent Patients with Severe and Refractory Atopic Dermatitis
An open multicenter study evaluating dupilumab in the treatment of moderate to severe atopic…
Subscribe
Most read on this topic
Journal on this topic
Related topic
Most read on this topic
- Dupilumab – The First Biologic Umbrellaing Type 2 Inflammation Treatment: How Does It Work and Who Is It For?
- Prim. MUDr. Gustáv Ondrejka: Biological treatment of asthma eliminates the need for systemic corticotherapy
- Skin conditions in patients with inflammatory bowel diseases
- Asthma bronchiale in the context of internal medicine
- Therapy with Cyclosporine in the Context of the Coronavirus Pandemic
- Dupilumab Now Covered for Atopic Dermatitis in Children Older Than 6 Years
Journal on this topic
Related topic